Current Treatment?
How it works?
Action clip showing the importance of treating the microvascular system – show visual breaking up and restoring flow.
CorFlow has developed the Controlled Flow Infusion (CoFI) System for MVO: Early diagnosis and targeted delivery of treatment in the cath lab, within minutes.
In-stent occlusion and controlled infusion combined with measurement of back-pressure response in less than 2 minutes.
Early assessment of microvascular status.
Address stent occlusion with intracoronary infusion of therapeutic agents in less than 10 minutes.
Delayed wash-out, increased dwelling time, “massage” of drug into obstructed vessels.
Microcirculatory / microvascular dysfunction remains an area of massive unmet need in >20M people annually – it accounts for 1/6 below-the-knee amputations, 1/4 ischemic stroke patients, and 1/2 of all INOCA patients (70% female)
Reperfusion injury occurs in multiple organs as “collateral damage” when restoring blood flow
The global reperfusion market today is highly fragmented, $1.4B with a 5% CAGR and ripe for disruption
CorFlow represents a new approach, including next generation AI utilization for both diagnostics and therapy delivery with drug/device combinations not previously feasible